ERBB2 and breast carcinoma: Targeted therapy is considered an appropriate choice to kill cancer cells more efficiently than non-targeted treatments, and also as a way to overcome systemic toxicity, especially in ErbB2-positive breast cancer patients undergoing conventional systemic chemotherapy, radiotherapy, or invasive surgery [5].